Evaluation of the Effect of Double Inhibition of Angiotensin II AT1 Receptor and Neprilysin Activity on Sympathic Nervous System Activity in Patient With Heart Failure
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- Acronyms B2AN-SNS
- 25 Oct 2017 Planned End Date changed from 1 Nov 2017 to 1 May 2019.
- 25 Oct 2017 Planned primary completion date changed from 1 Nov 2017 to 1 May 2019.
- 17 May 2017 Status changed from not yet recruiting to recruiting.